Price (delayed)
$3.3
Market cap
$288.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.12
Enterprise value
$127.99M
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver
There are no recent dividends present for TERN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.